Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q3 2024 Earnings Presentation

15 slides from Day One Biopharmaceuticals's earnings presentation, Oct 30, 2024

  1. Slide 1: Third Quarter 2024 Financial Results and Corporate Progress

    Third Quarter 2024 Financial Results and Corporate Progress October 2024 Nasdaq: DAWN

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc

  3. Slide 3: Agenda & Day One Participants

    Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM (tovorafenib) Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating Officer & Chief Financial Officer) Q&A Session All, joined by: Sam Blackman (Co-Founder & Head

  4. Slide 4: Opening Remarks

    Opening Remarks Jeremy Bender Chief Executive Officer

  5. Slide 5: Executing On Our Priorities As A Commercial-Stage Company

    Executing On Our Priorities As A Commercial-Stage Company 1 Represents cash, cash equivalents and short-term investments as of September 30, 2024. OJEMDA $20.1M in net product revenue +145% quarter over quarter growth Steady cadence of new patient starts and favorable payer access Pipeline Progress

  6. Slide 6: OJEMDA Launch Performance

    OJEMDA Launch Performance Lauren Merendino Chief Commercial Officer

  7. Slide 7: Impressive Performance on Multiple Fronts

    Impressive Performance on Multiple Fronts 1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2 Cumulative prescriptions are approximations based on data available on September 30, 2024. $28.3M NET REVENUES SINCE LAUNC

  8. Slide 8: Quarterly Net Revenue: OJEMDA Patient Demand Continues to Drive Growth

    Quarterly Net Revenue OJEMDA Patient Demand Continues to Drive Growth $8.2M $20.1M +145% Revenue Drivers Consistent patient demand & high continuation rates were primary growth drivers in Q3 The growth rate reflects ongoing adoption of OJEMDA by physicians, payers, and patients. High payer approval

  9. Slide 9: Strong Growth in Prescriptions in 3Q 2024

    Strong Growth in Prescriptions in 3Q 2024 1 Total prescriptions includes prescriptions for all patients (new & refill, paid & free drug and on-label & off-label patients). 2 Prescriptions are approximations based on data available on September 30, 2024. HCP – Health Care Professional. 239 619 +159%

  10. Slide 10: Physician Perspectives: Momentum Continues to Build

    Physician Perspectives Momentum Continues to Build in Physicians Treating pLGG 1 Day One Market Research, survey of 24 pLGG-treating Oncologiists. 2 Day One prescription data. 3 Guidepoints interview, 10/14/2024, 4 Day One Market Research. “From what I recall, over 80% of patients achieved at least

  11. Slide 11: Significant Progress on Payer Coverage

    Significant Progress on Payer Coverage, with Published Coverage for the Majority of Patients ~60% Commercial Patients 1 Breakaway Partners LLC – Breakaway Partners Analytics Platform. Metrics Based on 190.5M Commercial Lives . 2 Artia Solutions - Medicaid Coverage Status Report and Breakaway Partner

  12. Slide 12: Well-Positioned For Continuing Commercial Execution And Sustained Growth

    Well-Positioned For Continuing Commercial Execution And Sustained Growth Continuing Launch Trajectory Increase breadth & depth of prescribers Position OJEMDA as the standard of care in 2nd line Establish remaining payer coverage policies

  13. Slide 13: Financial Performance

    Financial Performance Charles York Chief Operating Officer and Chief Financial Officer

  14. Slide 14: Third Quarter 2024 Financial Results

    Third Quarter 2024 Financial Results All financial information is unaudited. 1 Includes stock-based compensation expense of $3.8 million and $13.2 million for the three and nine months ended 9/30/24, and $3.3 million and $10.1 million for the three and nine months ended 9/30/23, respectively. 2 Incl

  15. Slide 15: Day One Biopharmaceuticals

    Day One = BIOPHARMACEUTICALS

Day One Biopharmaceuticals — Q3 2024 Earnings Presentation on 6ix